The creation of cell lines is an art, which develops with practice and the adaptation of local resources to facilitate tissue growth.

Primary cultures represent (heterogeneous but still closely represent the parent cell types) freshly isolated cultures until sub-cultured. Several sub-cultures (passages) onto fresh media cause the cell lines either to transform (become continuous) or die. Sub-cultured cell lines may be different in morphology and have slight chromosomal variation when compared to the primary cultures. Cell lines grow attached to a solid surface but can also grow in an unattached suspension culture in some cases. The substrate used may affect cell behaviour.

The basic materials for the creation of cell lines include: chemicals, incubators (humidified incubators 37°C – 5% CO₂ and 95% air), snap freezing materials (liquid nitrogen), tissue culture and some instruments (size 15 blade scalpel and forceps) (Tables 1 and 2).

Chemicals are usually used for maintenance, as growth media and for separation of cells explants for cell lines (Table 2) and these procedures takes place in various universal tubes (Appendix 1).

Research and ethical approval is ideally obtained with regards the consent and subsequent tissue use. The voluntary nature of the process must be emphasized and no form of duress implied, ideally the process is carried out well ahead of any procedure. We present our current consent form for modification and usage (see Part II).

Prospective patient data is entered on a proforma or directly into a database detailing i.e. family history, carcinogenic exposure, TNM stage (with volumetric staging), previous and proposed treatment and duration with later entry of prognostic, morbidity and mortality data. A note is made of the anonimised patient sample number. These anonimised records are held in a secure computer and written form.

Controls may be selected on the basis of anatomy and/or exposure to carcinogens or previous treatment fields, i.e. in the head & neck region contralateral piriform fossa, non affected portion of tissues. Control tissue can be taken at fixed distances from the pathology edge, i.e.1, 2, 5 cm for assessment of field effect or suppressed potential or dormant pathology clones. This is carried out with the auspices of institutional ethics committee, research and development department and fully informed patient consent.

Each head & neck pathology must be taken into context, i.e. assessing the exposure to potentially contaminated body fluids, i.e. saliva, pus necessitating antimicrobial treatment or hypoxic conditions affecting viability and cell line growth.

A sample for histopathological confirmation of tissue type (pathology type, grade, histology of control tissue) is also always taken. Furthermore, confirmation of infection by microbiological culture and later confirmation of irradication of infection (i.e. by myoplasma PCR [polymerase chain reaction]) can be performed in house by the local microbiological laboratory.

For non mucosal non exposed head and neck pathologies, one hopes to sample non necrotic tissue. Here the risk of contamination is reduced but hypoxic factors may affect the pathological cell viability.

For mucosal (aero-digestive)/skin pathology with exposure to contamination, i.e. salivary content or skin flora, the risks of infection (i.e. mycoplasma) which may affect tissue growth and cellular response necessitating the use of appropriate antibiotics, antifungals or antivirals.

Processing is carried out in a sterile laminar airflow environment as is found in the typical operating theatre environment.

Tissue can be snap frozen within seconds of excision by full sample immersion in liquid nitrogen. Alternatively tissue may be placed in RNA'ase later (to prevent RNA loss) for later processing. Separate forceps and scalpel are used for primary, secondary, metastases and control tissue to reduce cross contamination of genetic material.

Pathological tissue is resected at the time of major surgery and material surplus to pathological diagnostic requirements is immediately divided into three parts. The first part (for DNA, RNA and protein extraction) is immersed in liquid nitrogen and the second part (for later immunohistochemical and in situ hybridisation studies) is frozen on dry ice and both are stored at -80°C. The third part is used for the establishment of cell lines according to the methodology described with monitor modifications.

A tissue sample, where material in excess of diagnostic requirements is available, is obtained from patients undergoing major surgical resection with curative or palliative intent. The establishment of pathological tissue cell lines is carried out as previously described with some modifications (Tables 1 and 2).

Biopsy material is soaked briefly in absolute alcohol (2–3 seconds) and then washed twice in DMEM containing 200 iu/ml penicillin, 200 ug/ml streptomycin and 5 ug/ml fungizone (This is in an attempt to prevent bacterial and fungal infections contaminating the cell lines).

Surgical specimens are further processed in cold "establishment media" consisting of DMEM/20% FCS with 2.5 ug/ml Amphotericin-B (Antifungal agent). Tissues are reduced to 0.5–1 mm³ fragments with crossed size 20 scalpel blades under aseptic conditions (this creates smaller potential tissue explants which have a larger surface area to volume ratio allowing the diffusion of nutrients, oxygen and wastes increasing the likelihood of growth of cells from the explant). After three washes with PBS containing 2.5 ug/ml Amphotericin-B, about 8–10 fragments are transferred either to:

a) A 25-cm² plastic culture flask containing not more than 3 ml of "establishment media". Cultures are maintained in humidified incubators at 37°C in an atmosphere of 5% CO₂ and 95% air for at least four days without disturbance. The medium is renewed twice weekly once the tissue fragments had become firmly attached. Within 7–10 days, migration of epithelial and fibroblast cells from the pathological explants should be apparent.

b) An incubation mixture of 5 ml of trypsin type III (SIGMA) containing 100 iu/ml penicillin, 100 ug/ml streptomycin, and 2.5 ug/ml fungizone initially at 4°C for 12 hours and then at 37°C for 30 minutes. The digested tissues are then resuspended in complete medium (DMEM containing 20% FCS, 100 iu/ml penicillin, 100 ug/ml streptomycin, 2.5 ug/ml fungizone, 0.075% additional sodium bicarbonate, 0.6 mg/ml additional L-glutamine and 0.5 ug/ml hydrocortisone) and seeded into 60 mm tissue culture Petri dishes.

All cultures are incubated in a humidified of 5% CO₂/95% air at 37°C air and the medium is changed twice weekly. In later culture passages, cell lines are grown in DMEM containing 10% FCS and free of all antibiotics (this in an attempt to encourage the cell line to revert back to a more 'natural' mode of behaviour not influenced by the chemical properties of the antibiotics).

Fibroblast outgrowth is controlled by selective detachment via mechanical removal using a cell-scraper or exposure to 0.05% trypsin/0.04% Na₂EDTA (this allows preferential detachment of selected cells improving the purity of the remaining cells). After the first passage, cultures are maintained in DMEM/10% FCS without anti-fungal agent. Cells then are subcultured at 95% confluence with a dilution of 1:6 to 1:8 and are stored frozen at -135°C.

New cell lines are used during passages 5–15, whereas fibroblasts and normal keratinocytes are used at passages 3 through 5. Human keratinocytes are established from primary cultures of normal oral mucosa and maintained in defined keratinocyte-serum free medium (SIGMA), (as their maintenance growth factor cf FCS).

All cell lines are cultured routinely at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. Cells are maintained in monolayer culture and passaged weekly by incubation with 0.01% bovine pancreatic trypsin in PBS containing 0.04% Na₂EDTA for about 3–5 min at 37°C. Detached cells were collected in DMEM/10% FCS, mixed into a single-cell suspension in a universal and pelleted by centrifugation in an IEC Centra-7 centrifuge for 3 minutes at 800 g. Following resuspension in fresh, pre-warmed medium, cell counts and viability estimation are carried out by making a dilution of cell suspension in trypan blue and counting using a haemocytometer counting chamber. Cells are diluted to the required density (1–5 × 10⁴/ml) before plating into culture flasks (5 ml/25 cm², 25 ml/80 cm2, 50 ml/170 cm²) or plates (200 ml/well of 96-well plates, 2 ml/well of 24-well plates, 5 ml/well of 6-well plates). Medium is replaced two or three times per week. Vigilance is kept for signs of microbial infection (bacterial or fungal), any cell aliquots that are infected should be discarded and all apparatus sterilised.

Cells of early passages and high viability (>80%) are stored at -135°C in liquid nitrogen (this slows their deterioration and allows later resurrection and specific experimental usuage making the process overall more efficient). Between 10⁶-10⁷ cells are pelleted by centrifugation and the supernatant is discarded. The cells are resuspended in 1 ml of an ice-cold freezing mixture containing 7% DMSO and 93% FCS and transferred to 1.5 ml cryo-tubes. After controlled freezing, the samples are immersed in liquid nitrogen. When required, aliquots of cells are thawed quickly at 37°C, diluted into 20 ml DMEM/10% FCS in a 30 ml universal tube. After centrifugation, the cells are washed once more with 20 ml of DMEM/10% FCS and then plated out into 25 cm² flasks. Liquid nitrogen storage enables one to maintain a large number of cell line aliquots of low passage number without the need to immortalise the cell lines by transfections which may change their behaviour further away from that of the pathology of origin. By doing this a large number of experiments can be efficiently carried out with minimal loss of the 'natural pathological cell' behaviour.

Tissue is stored in cryotubes in liquid nitrogen containers. For material refrigerated at -80°C a back up power supply and fail safe is essential. In either case the shelf position or row is noted as is the numbered cryotube label with an encryption code based on an algorithm that codes for the unique patient identity. These anonimised records are held in a secure computer and written form. It is essential data is collected prospectively.

An example of some head and neck cell lines developed using this protocol. HN1a represents primary oral tumour whilst HN1b represents a cell lines derived from a lymphatic metastasis. HN2 represents a similar primary oropharyngeal tumour (A) and secondary (B) cell line; we also illustrate the change in morphology of the cell depending on substrate (plastic and collagen). Note the changed growth pattern in the metastatic cell lines (Figures 1, 2, 3, 4, 5 and 6).

Initially we were successful in 30% of cases but as experience grew, we developed cell lines in over 70% of cases. The main difficulties tended to be infection (resolved with strict sampling testing and cleaning of cell lines) and lack of viability (resolved by sampling away from areas of tumour necrosis). Fibroblast contamination was control by differential washes and mechanical detachment.